Background <p>ABBV-368 is a humanized monoclonal antibody that targets the costimulatory receptor OX40. Here, we investigate a treatment strategy with ABBV-368 combined with the investigational toll-like receptor 9 agonist tilsotolimod, the programmed cell death 1 inhibitor budigalimab, and nab-paclitaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). To our knowledge, this is the first…
Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma
Journal for ImmunoTherapy of Cancer | | Daste, A., Le, X., Makkouk, A., Patel, M., Le Tourneau, C., Perets, R., Popovtzer, A., Ochsenreither, S., Haderlein, M., Oliva, M., Sukari, A., Hong, J., Blaney, M., Ramathal, C., McDevitt, M., Rosenberg, A. J.
Topics: cervical-cancer, targeted-therapy, chemotherapy, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer